Baker Bros. Advisors as of Sept. 30, 2012
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 70 positions in its portfolio as reported in the September 2012 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Genomic Health | 7.2 | $89M | 11M | 7.91 | |
27 Incyte | 5.4 | $67M | 15M | 4.55 | |
XOMA CORP Common equity shares | 4.6 | $57M | 16M | 3.69 | |
Medivation | 4.4 | $55M | 967k | 56.35 | |
Auxilium | 4.3 | $53M | 6.3M | 8.47 | |
Gilead Sciences (GILD) | 4.0 | $49M | 740k | 66.33 | |
Biomarin Pharmaceutical Inc note 1.875% 4/2 | 3.9 | $48M | 23M | 2.08 | |
44 Synageva Biopharma | 3.8 | $47M | 8.4M | 5.60 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 3.7 | $45M | 811k | 55.89 | |
55 Incyte Genomics Notes 4.75% 10/1/2015 conv bonds | 3.2 | $39M | 158M | 0.25 | |
Spectrum Pharmaceuticals | 3.1 | $39M | 3.3M | 11.70 | |
37 Pharmacyclics | 3.1 | $38M | 11M | 3.33 | |
9 Ariad Pharmaceuticals | 2.8 | $35M | 5.6M | 6.27 | |
Intermune cv 5.0% | 2.7 | $34M | 34M | 0.99 | |
Gilead Sciences conv | 2.7 | $34M | 22M | 1.56 | |
Clovis Oncology | 2.7 | $33M | 1.6M | 20.45 | |
Medivation Inc note 2.625% 4/0 | 2.7 | $33M | 25M | 1.35 | |
60 Salix 2.75% 5/15/15 conv bonds | 2.4 | $30M | 111M | 0.27 | |
45 Viropharma | 2.3 | $29M | 11M | 2.63 | |
BioCryst Pharmaceuticals (BCRX) | 1.9 | $24M | 5.6M | 4.24 | |
41 Seattle Genetics | 1.6 | $21M | 19M | 1.06 | |
Exelixis Inc cnv | 1.6 | $20M | 19M | 1.04 | |
D Tranzyme | 1.6 | $20M | 4.4M | 4.46 | |
Onyx Pharmaceuticals | 1.5 | $18M | 215k | 84.50 | |
Repros Therapeutics | 1.4 | $18M | 1.2M | 15.23 | |
32 Infinity Pharmaceuticals | 1.4 | $17M | 724k | 23.51 | |
Vertex Pharmaceuticals Inc note 3.350%10/0 | 1.3 | $16M | 13M | 1.29 | |
61 Salix 144a 1.5% 3/15/19 conv bonds | 1.3 | $16M | 222M | 0.07 | |
Halozyme Therapeutics (HALO) | 1.1 | $13M | 1.8M | 7.54 | |
BioDelivery Sciences International | 1.1 | $14M | 2.1M | 6.32 | |
ACADIA Pharmaceuticals (ACAD) | 1.1 | $13M | 5.2M | 2.53 | |
Derma Sciences | 1.0 | $13M | 1.2M | 10.38 | |
Intermune Inc note 2.500% 9/1 | 1.0 | $13M | 17M | 0.76 | |
XenoPort | 1.0 | $12M | 1.0M | 11.45 | |
Threshold Pharma | 0.9 | $11M | 1.5M | 7.24 | |
Synta Pharmaceuticals | 0.8 | $10M | 1.3M | 7.62 | |
United Therapeutics Corporation (UTHR) | 0.7 | $9.2M | 165k | 55.88 | |
Aegerion Pharmaceuticals | 0.7 | $9.1M | 615k | 14.82 | |
BioMarin Pharmaceutical (BMRN) | 0.7 | $8.1M | 200k | 40.26 | |
InterMune | 0.6 | $7.8M | 868k | 8.96 | |
Synergy Pharmaceuticals | 0.6 | $7.7M | 1.6M | 4.78 | |
Qlt | 0.6 | $7.4M | 950k | 7.79 | |
Cerus Corporation (CERS) | 0.6 | $7.2M | 2.1M | 3.40 | |
Array BioPharma | 0.5 | $5.8M | 1.0M | 5.84 | |
Ym Biosciences | 0.5 | $5.7M | 3.1M | 1.84 | |
Zogenix | 0.4 | $5.3M | 2.0M | 2.64 | |
United Therapeutics conv | 0.4 | $5.2M | 4.0M | 1.31 | |
Questcor Pharmaceuticals | 0.4 | $4.6M | 250k | 18.47 | |
Alere Inc note 3.000% 5/1 | 0.3 | $4.3M | 4.5M | 0.95 | |
Amicus Therapeutics (FOLD) | 0.3 | $4.0M | 765k | 5.20 | |
Anacor Pharmaceuticals | 0.3 | $3.7M | 568k | 6.58 | |
Chelsea Therapeutics International | 0.3 | $3.6M | 3.0M | 1.20 | |
Discovery Laboratories | 0.3 | $3.4M | 1.0M | 3.27 | |
Anthera Pharmaceuticals | 0.2 | $2.9M | 2.9M | 0.99 | |
Durata Therapeutics | 0.2 | $3.0M | 319k | 9.40 | |
59 Salix 5.5% 8/15/28 conv bonds | 0.2 | $2.4M | 22M | 0.11 | |
INC Ventrus Biosciences | 0.1 | $1.7M | 481k | 3.58 | |
Biodel | 0.1 | $1.6M | 540k | 2.97 | |
ZIOPHARM Oncology | 0.1 | $1.4M | 254k | 5.45 | |
Ligand Pharmaceuticals | 0.1 | $1.3M | 73k | 17.15 | |
Chemocentryx | 0.1 | $582k | 50k | 11.64 | |
ArQule | 0.0 | $440k | 86k | 5.11 | |
Exelixis (EXEL) | 0.0 | $441k | 91k | 4.83 | |
Cubist Pharmaceuticals | 0.0 | $238k | 5.0k | 47.60 | |
Alere | 0.0 | $262k | 1.3k | 202.63 | |
Idera Pharmaceuticals | 0.0 | $297k | 288k | 1.03 | |
Cumberland Pharmaceuticals (CPIX) | 0.0 | $153k | 24k | 6.48 | |
Cyclacel Pharmaceuticals Inc pfd conv ex 6% (CYCCP) | 0.0 | $67k | 21k | 3.19 | |
Sequenom | 0.0 | $46k | 13k | 3.57 | |
Aradigm Corporation (ARDM) | 0.0 | $13k | 100k | 0.13 |